Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137353 | 0.78 | CYP1A2 (0.31) | CYP1A2CYP2A6TSHR | |
| SCHEMBL21050685 | 0.78 | GPR84 (0.30) | — | |
| SCHEMBL3696572 | 0.73 | CYP2A6 (0.50) | CYP1A2CYP2A6TSHR | |
| SCHEMBL247299 | 0.72 | GPR84 (0.36) | CYP1A2 | |
| SCHEMBL31227814 | 0.71 | CYP1A2 (0.42) | CYP1A2CYP2A6 | |
| SCHEMBL31723362 | 0.70 | GPR84 (0.30) | — | |
| SCHEMBL3579335 | 0.69 | ACHE (0.39) | — | |
| SCHEMBL31280106 | 0.69 | ACHE (0.39) | — | |
| SCHEMBL13659534 | 0.68 | ALDH1A1 (0.52) | CYP1A2CYP2A6TSHR | |
| SCHEMBL19706810 | 0.68 | CYP2A6 (0.52) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | ASTRAZENECA, AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| CN-113508118-A | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| EP-3790884-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | Astrazeneca AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| CN-112074520-A | Tetracycloheteroaryl compounds | 阿斯利康(瑞典)有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CYP1A2 106/4885CYP2A6 142/4885TSHR 2965/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CYP1A2 106/4885CYP2A6 142/4885TSHR 2965/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | CYP1A2 464/4885CYP2A6 1071/4885TSHR 2944/4885 |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | CCNI, MCL1, MKI67 | CYP1A2 126/4885CYP2A6 111/4885TSHR 701/4885 |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | CCNI, MCL1, MKI67 | CYP1A2 126/4885CYP2A6 111/4885TSHR 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.